Pioglitazone: Beyond glucose control

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 8, 2010, Pages 1057-1067

  De Pablos Velasco, Pedro ^a  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

cardiovascular; diabetes; glucose control; pioglitazone; PPAR

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; METFORMIN; METFORMIN PLUS PIOGLITAZONE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ARTERIAL WALL THICKNESS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; FOLLOW UP; FRACTURE; GLYCEMIC CONTROL; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; ADIPOSE TISSUE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LIVER; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; ADMINISTRATION, ORAL; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; THIAZOLIDINEDIONES;

EID: 77955187964     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.98     Document Type: Review

References (78)

1. American Diabetes Association. Position statement: standards of medical care in diabetes. Diabetes Care 32(Suppl. 1), S13-S61 (2009).
2. Laakso M. Hyperglycemia and cardiovascular disease in Type 2 diabetes. Diabetes 48(5), 937-942 (1999). (Pubitemid 29226337)
3. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 281(14), 1291-1297 (1999).
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
5. Bueno H, Hernaez R, Hernandez AV. Type 2 diabetes mellitus and cardiovascular disease in Spain: a narrative review. Rev. Esp. Cardiol. 8(Suppl. C), 53C-61C (2008).
6. Escobar C, Barrios V, Calderon A et al. Diabetes mellitus in hypertensive population attended in primary care in Spain. Blood pressure and lipid control rates. Rev. Clin. Esp. 207(5), 221-227.
7. Stults B, Jones RE. Management of hypertension in diabetes. Diabetes Spectr. 19, 25-31 (2006).
8. Ostergren J, Poulter NR, Sever PS et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with Type II diabetes. J. Hypertens. 26(11), 2103-2111.
9. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Engl. J. Med. 348(5), 383-393 (2003). (Pubitemid 36159355)
10. Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in Type 2 diabetes: systematic review and meta-analysis. PLoS One 4(7), e6112 (2009).
11. UKPDS Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of Type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44(11), 1249-1258 (1995).
12. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: a 6-month randomized placebo-controlled dose- response study. The Pioglitazone 001 Study Group. Diabetes Care 23(11), 1605-1611 (2000).
13. Scherbaum WA, Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with Type 2 diabetes: a double-blind, placebo- controlled study. Horm. Metab. Res. 34(10), 589-595 (2002).
14. Herz M, Johns D, Reviriego J et al. A randomized, double-blind, placebo- controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin. Ther. 25(4), 1074-1095 (2003).
15. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; for The QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet. Med. 22(4), 399-405 (2005).
16. Tan MH, Baksi A, Krahulec B et al.; for the GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with Type 2 diabetes. Diabetes Care 28(3), 544-550 (2005).
17. Barnett AH. Redefining the role of thiazolidinediones in the management of Type 2 diabetes. Vasc. Health Risk Manag. 5(1), 141-151 (2009).
18. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROACTIVE study (Prospective Pioglitazone Clinical Trial In Macrovascular Events): a randomised controlled trial. Lancet 366(9493), 1279-1289 (2005).
19. Hanefeld M. Pioglitazone and sulfonylureas: effectively treating Type 2 diabetes. Int. J. Clin. Pract. Suppl. 153, 20-27 (2007).
20. Schondorf T, Karagiannis E, Posseldt RE, Forst T, Pfutzner A. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in Type 2 diabetes patients with insufficient glycemic control by metformin alone - results from a post-marketing surveillance trial under daily routine conditions. Diabetes Technol. Ther. 11(6), 379-383 (2009).
21. Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. Int. J. Clin. Pract. 63(6),912-929( 2009).
22. Kaku K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with Type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Curr. Med. Res. Opin. 25(5), 1111-1119 (2009).
23. Hanefeld M. The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes Obes. Metab. 11(8), 742-756 (2009).
24. Chogtu B, Singh NP, Chawla S, Gupta U. Impact of glitazones on metabolic and haemodynamic parameters in patients with Type 2 diabetes mellitus. Singapore Med. J. 50(4), 395-399 (2009).
25. Aso Y, Hara K, Ozeki N et al. Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled Type 2 diabetes. Diabetes Res. Clin. Pract. 85(2), 147-152 (2009).
26. Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. J. Diabetes Complicat. DOI: 10.1016/j.jdiacomp. 2009.05.004 (2009) (Epub ahead of print).
27. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 24(1), 29-33 (2004).
28. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors, Endocr. Rev. 26(3), 439-451 (2005).
29. Hanefeld M. Pioglitazone and sulfonylureas: effectively treating Type 2 diabetes. Int. J. Clin. Pract. Suppl. 153, 20-27 (2007).
30. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P. Insulin-based versus triple oral therapy for newly-diagnosed Type 2 diabetes: which is better? Diabetes Care 32(10), 1789-1795 (2009).
31. Hanefeld M, Pfutzner A, Forst T, Lubben G. Glycemic control and treatment failure with pioglitazone versus glibenclamide in Type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr. Med. Res. Opin. 22, 1211-1215 (2006).
32. Mazzone T, Meyer PM, Feinstein SB et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA 296(21), 2572-2581 (2006).
33. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299(13), 1561-1573 (2008). (Pubitemid 351482795)
34. Defronzo RA, Banerji M, Bray GA et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr. Disord. 9, 17 (2009).
35. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of Type 2 diabetes mellitus. Diabetes 58(4), 773-795 (2009).
36. Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic p-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55(2), 517-522 (2006).
37. Schneider F, Vossler S, Franke S, Bar F, Konrad T. Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. Int. J. Clin. Pharmacol. Ther. 47(5), 311-320 (2009).
38. Harashima K, Hayashi J, Miwa T, Tsunoda T. Long-term pioglitazone therapy improves arterial stiffness in patients with Type 2 diabetes mellitus. Metabolism 58(6), 739-745 (2009).
39. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation115(10), 1285-1295 (2007).
40. Tsuchiya K, Akaza I, Yoshimoto T, Hirata Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in Type 2 diabetes. Endocr. J. 56(5), 691-698 (2009).
41. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocrinol. Metab. 86(7), 3452-3456 (2001).
42. Davidson M, Meyer PM, Haffner S et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone- mediated reduction of carotid intima- media thickness progression in patients with Type 2 diabetes mellitus. Circulation 117(16), 2123-2130 (2008).
43. Takagi T, Okura H, Kobayashi Y et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in Type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc. Interv. 2(6), 524-531 (2009).
44. Kaneda H, Shiono T, Miyashita Y et al. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. Heart 95(13), 1079-1084 (2009).
45. Pantalone KM, Kattan MW, Yu C et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in Type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 46(2), 145-154 (2009).
46. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROACTIVE): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients. Diabetes Care 27(7), 1647-1653 (2004).
47. Bottomley J, Palmer A, Williams R, Massi-Benedetti M, Dormandy J. PROACTIVE 03: pioglitazone, Type 2 diabetes and reducing macrovascular events - economic implications. Br. J. Diabetes Vasc. Dis. 6, 63-70 (2006).
48. Wilcox R, Bousser M-G, Pirag V et al. PROACTIVE 04: Effects of pioglitazone in patients with Type 2 diabetes with or without previous stroke - results from PROACTIVE (Prospective Pioglitazone Clinical Trial In Macrovascular Events). Stroke 38(3), 865-873 (2007).
49. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; on behalf of the PROACTIVE investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with Type 2 diabetes and previous myocardial infarction - results from PROACTIVE (PROACTIVE 05). J. Am. Coll. Cardiol. 49(17), 1772-1780 (2007).
50. Valentine WJ, Bottomley JM, Palmer AJ et al.; on behalf of the PROACTIVE Study Group. PROACTIVE 06: Cost effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet. Med. 4(9), 982-1002 (2007).
51. Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B. PROACTIVE 07: Pioglitazone in the treatment of Type 2 diabetes: results of the PROACTIVE study. Vasc. Health Risk Manag. 3(4), 355-370 (2007). (Pubitemid 47542597)
52. Erdmann E, Charbonnel B, Wilcox RG et al.; on behalf of the PROACTIVE investigators. Pioglitazone use and heart failure in patients with Type 2 diabetes and preexisting cardiovascular disease: data from the PROACTIVE study (PROACTIVE 08). Diabetes Care 30(11), 2773-2778 (2007).
53. Schneider CA, Ferrannini E, DeFronzo R, Schernthaner G, Yates J, Erdmann E. Effect of pioglitazone on cardiovascular outcome in patients with diabetes and chronic kidney disease. J. Am. Soc. Nephr. 19(1), 182-187 (2008).
54. Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with Type 2 diabetes: Results from PROACTIVE (PROACTIVE 10). Am. Heart J. 155(4), 712-717 (2008).
55. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; on behalf of the PROACTIVE Investigators. Impact of peripheral arterial disease in patients with diabetes - results from PROACTIVE (PROACTIVE 11). Atherosclerosis 202(1), 272-281 (2009).
56. Spanheimer R, Betteridge DJ, Tan MH, Ferrannini E, Charbonnel B; PROACTIVE Investigators. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROACTIVE experience (PROACTIVE 14). Am. J. Cardiol. 104(2), 234-239 (2009).
57. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. Br. Med. J. 339, b2942 (2009).
58. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with Type 2 diabetes mellitus. Coron. Artery Dis. 128(5), 413-423 (2001).
59. Gupta AK, Smith SR, Greenway FL, Bray GA. Pioglitazone treatment in Type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes. Metab. 11(4), 330-337 (2009).
60. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355(22), 2297-2307 (2006).
61. Chaggar PS, Shaw SM, Williams SG. Thiazolidinediones and heart failure. Diab.Vasc. Dis. Res. 6(3), 146-152 (2009).
62. Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with Type 2 diabetes mellitus treated with pioglitazone for 2 years. Clin. Ther. 31(1), 74-88 (2009).
63. Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with Type 2 diabetes. Cardiovasc. Diabetol. 8, 15 (2009).
64. Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT. Association between congestive heart failure and hospitalization in patients with Type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin. Ther. 26(9), 1400-1410 (2004).
65. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and Type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.Lancet 370(9593), 1129-1136 (2007).
66. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298(10), 1180-1188 (2007).
67. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with Type 2 diabetes: an overview of data from PROactive. DrugSaf. 32(3), 187-202 (2009).
68. van der Meer RW, Rijzewijk LJ, de Jong HW et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled Type 2 diabetes mellitus. Circulation 119(15), 2069-2077 (2009).
69. Liazos E, Broadbent DM, Beare N, Kumar N. Spontaneous resolution of diabetic macular edema after discontinuation of thizolidinediones. Diabet. Med. 25(7), 860-862 (2008).
70. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo- controlled trial. J. Clin. Endocrinol. Metab. 93(5), 1696-1701 (2008).
71. Meymeh RH, Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 177(7), 723-724 (2007).
72. George J, Hannah S, Lang CC. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. Cardiovasc. Ther. 27(2), 83-88 (2009).
73. Nathan DM, Buse JB, Davidson MB et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1), 193-203 (2009).
74. Nathan DM, Buse JB, Davidson MB et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in Type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52(1), 17-30 (2009).
75. St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. Curr. Med. Res. Opin. 25(6), 1343-1353 (2009).
76. Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in Type 2 diabetes patients with a history of macrovascular disease: a German perspective. CostEff. Resour. Alloc. 7, 9 (2009).
77. Brandle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ. Cost- effectiveness of pioglitazone in patients with Type 2 diabetes and a history of macrovascular disease in a Swiss setting. SwissMed. Wkly 139(11-12), 173-184 (2009).
78. European Medicines Agency Actos: European Public Assessment Report (2007) www.emea.europa.eu/humandocs/PDFs/ EPAR/Actos/H-285-PI-es.pdf Published 04/05/09